Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 5/20 | 0.38 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.35 |
| ▸ | HTR4 | Q13639 | 4/20 | 0.32 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | WHR1 | P49842 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14514511 | 0.82 | — | — | |
| SCHEMBL12258869 | 0.81 | PARP1 (0.42) | PARP1PARP2TLR9TLR8TLR7 | |
| SCHEMBL9910973 | 0.80 | DRD4 (0.35) | PARP1 | |
| SCHEMBL16906814 | 0.76 | HRH3 (0.36) | PARP1HRH3TLR9TLR7ALDH1A1 | |
| SCHEMBL15448160 | 0.76 | — | — | |
| SCHEMBL16887634 | 0.73 | PARP1 (0.42) | PARP1KCNH2ALDH1A1 | |
| SCHEMBL7856962 | 0.73 | — | — | |
| SCHEMBL2335166 | 0.73 | ALDH1A1 (0.38) | ALDH1A1 | |
| SCHEMBL18925951 | 0.72 | HRH3 (0.48) | HRH3KCNH2ALDH1A1 | |
| SCHEMBL10407881 | 0.71 | PARP1 (0.40) | PARP1PARP2TLR9TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3929203-A1 | DERIVATIVES OF AMPHOTERICIN B | Sfunga Therapeutics, Inc. (US) | 2021-12-29 | — | — | EP | disclosed |
| US-10882883-B2 | Derivatives of amphotericin B | SFUNGA THERAPEUTICS, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-20200262858-A1 | DERIVATIVES OF AMPHOTERICIN B | ELION THERAPEUTICS, INC. | 2020-08-20 | — | — | US | disclosed |
| US-20200190095-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | ABS DEVELOPMENT 1, INC. | 2020-06-18 | — | — | US | disclosed |
| US-20200039943-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SIGILON THERAPEUTICS, INC. | 2020-02-06 | — | — | US | disclosed |
| US-20190256494-A1 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2019-08-22 | — | — | US | disclosed |
| US-10188654-B2 | Uses of pyrimido-pyridazinones to treat cancer | ASANA BIOSCIENCES, LLC (US) | 2019-01-29 | — | — | US | disclosed |
| US-10183944-B2 | Pyrimido-pyridazinone compounds and methods of use thereof | ASANA BIOSCIENCES, LLC (US) | 2019-01-22 | — | — | US | disclosed |
| US-9957290-B2 | Derivatives of amphotericin B | SFUNGA THERAPEUTICS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-9957290-B2 | Derivatives of amphotericin B | SFUNGA THERAPEUTICS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170157126-A1 | USES OF PYRIMIDO-PYRIDAZINONES TO TREAT CANCER | ASANA BIOSCIENCES, LLC (US) | 2017-06-08 | — | — | US | disclosed |
| US-20170157126-A1 | USES OF PYRIMIDO-PYRIDAZINONES TO TREAT CANCER | ASANA BIOSCIENCES, LLC (US) | 2017-06-08 | — | — | US | disclosed |
| WO-2016168568-A1 | DERIVATIVES OF AMPHOTERICIN B | Revolution Medicines, Inc. (US) | 2016-10-20 | — | — | WO | disclosed |
| US-20160304548-A1 | Derivatives of Amphotericin B | ELION THERAPEUTICS, INC. | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183944-B2 | Pyrimido-pyridazinone compounds and methods of use thereof | THPO, TYMP, TYMS | PARP1 237/4885PARP2 443/4885HRH3 866/4885 |
| US-20200039943-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SLC10A1, SLCO1B3, SLC5A1 | PARP1 4804/4885PARP2 4860/4885HRH3 816/4885 |
| US-20160304548-A1 | Derivatives of Amphotericin B | C9, ERG28, AMPD3 | PARP1 3099/4885PARP2 3545/4885HRH3 653/4885 |
| US-10188654-B2 | Uses of pyrimido-pyridazinones to treat cancer | MKI67, DPYD, TYMP | PARP1 1868/4885PARP2 1989/4885HRH3 2015/4885 |
| US-20170157126-A1 | USES OF PYRIMIDO-PYRIDAZINONES TO TREAT CANCER | MKI67, DPYD, TYMP | PARP1 1868/4885PARP2 1989/4885HRH3 2015/4885 |
| US-10882883-B2 | Derivatives of amphotericin B | C9, ERG28, AMPD3 | PARP1 3099/4885PARP2 3545/4885HRH3 653/4885 |
| US-20200190095-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | THPO, TYMP, TYMS | PARP1 237/4885PARP2 443/4885HRH3 866/4885 |
| US-20190256494-A1 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABHD6, ABHD16A, RABL6 | PARP1 4316/4885PARP2 3998/4885HRH3 926/4885 |
| US-20200262858-A1 | DERIVATIVES OF AMPHOTERICIN B | C9, ERG28, AMPD3 | PARP1 3099/4885PARP2 3545/4885HRH3 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.